SLC2A1 and epilepsy: Group 3 comprised patients for whom treatment with KD was introduced at V0 for reasons other than MD: drug-resistant epilepsy (n = 8) or deficiency of glucose transporter GLUT1 (pathogenic variant in gene SLC2A1) (n = 2).